Rare and Orphan Diseases
14
Episodes 1-16 of 32
- Clinician's Roundtable
Etranacogene Dezaparvovec for Hemophilia B: Efficacy and Safety Four Years Post-Infusion
- Prev
- Next
Etranacogene Dezaparvovec for Hemophilia B: Efficacy and Safety Four Years Post-Infusion